Alpha Tau Medical Ltd-cl A (DRTS)

$2.4

-0.09

(-3.61%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Alpha Tau Medical Ltd-cl A

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 68.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.5% return, outperforming this stock by 314.8%

Performance

  • $2.40
    $2.56
    $2.40
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.25%

    Upside

    6.25%

    downward going graph
  • $2.40
    $4.80
    $2.40
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :50.0%

    Upside

    50.0%

    downward going graph

Returns

PeriodAlpha Tau Medical Ltd-cl ASector (Health Care)Index (Russel 2000)
3 Months
-21.2%
1.1%
0.0%
6 Months
-25.89%
12.5%
0.0%
1 Year
-15.88%
6.9%
2.2%
3 Years
-74.33%
14.3%
-23.0%

Highlights

Market Capitalization
174.2M
Book Value
$1.21
Earnings Per Share (EPS)
-0.42
Wall Street Target Price
9.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.6%
Return On Equity TTM
-30.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-34.6M
Diluted Eps TTM
-0.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.51
EPS Estimate Next Year
-0.56
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Alpha Tau Medical Ltd-cl A(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 285.42%

Current $2.40
Target $9.25

Technicals Summary

Sell

Neutral

Buy

Alpha Tau Medical Ltd-cl A is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alpha Tau Medical Ltd-cl A
Alpha Tau Medical Ltd-cl A
-14.73%
-25.89%
-15.88%
-74.33%
-75.35%
Moderna, Inc.
Moderna, Inc.
1.34%
41.81%
-16.73%
-38.71%
314.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alpha Tau Medical Ltd-cl A
Alpha Tau Medical Ltd-cl A
NA
NA
NA
-0.51
-0.31
-0.2
NA
1.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alpha Tau Medical Ltd-cl A
Alpha Tau Medical Ltd-cl A
Buy
$174.2M
-75.35%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
314.51%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Easterly Investment Partners.

    0.47%

  • Morgan Stanley - Brokerage Accounts

    0.44%

  • Hoylecohen, LLC

    0.39%

  • Corbin Capital Partners LP

    0.37%

  • HighTower Advisors, LLC

    0.31%

  • Atalaya Capital Management LP

    0.11%

Company Information

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.

Organization
Alpha Tau Medical Ltd-cl A
Employees
121
CEO
Mr. Uzi Sofer
Industry
Healthcare

Discover More

FAQs